Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient

Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient

In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjögren’s syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with P...

Full description

Bibliographic Details
Main Authors: Aaron Caeyman, Olivia Vandekerckhove, Karin Pat, Jokke Wynants, Karolien Weytjens, Isabelle De Wergifosse, Kristof Cuppens
Format: Article
Language:English
Published: Karger Publishers 2023-10-01
Series:Case Reports in Oncology
Subjects:
sjögren’s syndrome
sicca syndrome
pembrolizumab
immune checkpoint inhibition
non-small cell lung carcinoma
immune-related adverse event
case report
Online Access:https://beta.karger.com/Article/FullText/532098
Description
Summary:In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjögren’s syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with PD-1 inhibition (pembrolizumab).
ISSN:1662-6575

Similar Items